How has been the historical performance of Evoq Remedies?

Answer:The historical performance of Evoq Remedies shows fluctuations in key financial metrics over the years, with notable changes in net sales, operating profit, and profit after tax.

Breakdown:
Evoq Remedies experienced a significant increase in net sales from Mar'24 to Mar'25, rising from 4.05 Cr to 11.76 Cr, although this was a decrease from the previous year, Mar'23, where sales peaked at 20.39 Cr. Total operating income followed a similar trend, reflecting the same values as net sales. The company's total expenditure, however, increased sharply to 13.99 Cr in Mar'25 from 5.69 Cr in Mar'24, leading to an operating profit (PBDIT) of -2.23 Cr in Mar'25, which indicates a loss compared to the profit of 0.62 Cr in Mar'24. Profit before tax also decreased to 0.13 Cr in Mar'25 from 0.61 Cr in Mar'24, resulting in a profit after tax of 0.09 Cr in Mar'25, down from 0.45 Cr in Mar'24. On the balance sheet, total assets grew to 50.01 Cr in Mar'25 from 36.86 Cr in Mar'24, while total liabilities also increased to 50.01 Cr from 36.86 Cr, indicating a rise in financial obligations. The cash flow from operating activities showed a negative trend with -14.00 Cr in Mar'25, contrasting with a positive cash flow of 5.00 Cr in Mar'24, highlighting challenges in cash generation. Overall, Evoq Remedies has shown variability in its financial performance, with a notable decline in profitability and cash flow in the most recent year.